Genelux (GNLX) Current Deferred Revenue (2022)
Genelux's (GNLX) quarterly Current Deferred Revenue came in at $170000.0 in Q4 2022.
Genelux (GNLX) Current Deferred Revenue (2022) Analysis & Trends
Genelux's Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $170000.0 for Q4 2022.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $170000.0 in Q4 2022; TTM through Dec 2022 was $170000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $170000.0, changed N/A from the prior year.
- Current Deferred Revenue steadied at $170000.0 in Q4 2022 per GNLX's latest filing.
- Across five years, Current Deferred Revenue topped out at $170000.0 in Q4 2022 and bottomed at $170000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 170,000.00 |